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Renal cell carcinoma (RCC) is traditionally considered to be resistant to conventional low dose radiation
therapy (RT). The emergence of image-guided stereotactic body radiation therapy (SBRT) made it
possible to deliver much higher doses of radiation. Recent clinical trials of SBRT for RCC showed
improvement in local control rates and acceptable toxicity. Here we report a case of inoperable symp-
tomatic RCC that was managed with SBRT. Strikingly, the presenting symptoms of gross hematuria and
severe anemia were completely resolved following a course of SBRT. Thus, our case report highlights the
potential beneﬁt of this technique for patients with inoperable RCC.
 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The incidence of renal cell carcinoma (RCC) is gradually
increasing, with 61,560 new cases and 14,080 deaths reported in
2015.1 The common presenting symptoms of RCC are hematuria,
ﬂank pain and ﬂank mass.2 The standard of care for the stage IeIII
RCC is nephrectomy,2 either open or laparoscopic. RCC was tradi-
tionally considered to be resistant to conventional radiation ther-
apywith doses up to 6 Gy having little effect on tumor cell viability.3
While early studies in the 70s and 80s failed to show a signiﬁcant
clinical beneﬁt of a conventional post-operative radiation therapy,4
more recent trials that used a high dose image-guided adjuvant RT
demonstrated a signiﬁcant reduction of loco-regional failure.5 Ste-
reotactic radiotherapy ablation showed some promise in patients
with unresectable renal cancer, but more studies are needed to
further evaluate this approach in patients with inoperable RCC.5
Here, we report a case of unresectable renal mass with radio-
graphic features of the renal cell carcinoma that was treated with
ionizing radiation.Charles E Schmidt College of
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Our patient is a pleasant 85 year old malewith a 3 year history of
metastatic adenocarcinoma of the lung, in remission, s/p chemo-
therapy (Carboplatin and Trimetrexate), on Pemetrexed mainte-
nance chemotherapy, who presented with gross hematuria. He was
found to have Hg of 10, Hct 32.1, andMCV 81.7. Renal imaging (CT of
abdomen and pelvis) revealed a partially calciﬁed enhancing mass
in the anterior mid right kidney with inﬁltration and expansion of
the adjacent calyx, and bilateral renal cysts (Fig. 1). Radiographic
ﬁndings were suspicious for a renal cell carcinoma. Cystoscopy
performed by his urologist conﬁrmed the renal mass to be the
source of his bleeding. Renal angiography and subsequent emboli-
zation were performed in an effort to treat hematuria and anemia
associated with RCC. Right renal embolization resulted in the
temporary relief of patient’s symptoms. However, about 1 year later,
patient had a recurrence of a gross hematuria with a resultant
anemia (Hg 7.8, Hct 23.9, MCV 82.7) requiring multiple blood
transfusions. Patient was not felt to be a good surgical candidate
and biopsy was not performed due to high risk of bleeding. A
follow-up MRI of the abdomen with and without contrast showed
an irregular slightly contrast enhancing lobulated mass projecting
off the anterior mid-portion of the right kidney (Fig. 2). Since there
was enough circumstantial evidence to suggest that the renal mass
represented a renal cell carcinoma, and given the lack of other
treatment options, a palliative SBRT of renal mass was proposed asBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CT scan of the abdomen and pelvis demonstrating a partially calciﬁed mass in
the right kidney with inﬁltration and expansion of the adjacent calyx, and bilateral
renal cysts.
Figure 3. Axial image of the abdominal CT scan showing radiation dose distribution
within the right kidney mass (pink, red and yellow lines) with the right kidney
highlighted in green, and the adjacent bowel in blue colors.
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with SBRT over the course of 5 days with 5 fractions, 8 Gy per
fraction. He received 4000 cGy to the inner ITV and 3500 cGy to the
outer PTV. Overall, dose was limited secondary to the adjacent
bowel (Fig. 3). An early biologically effective dose (BED) range for
35/5e40/5 Gy was calculated to be 59.51e92.46 Gy (a/b ¼ 6.1). Six
weeks following the completion of the treatment patient was still
complaining of intermittent hematuria, although the color of his
urine was not as dark as the one before treatment. Remarkably, this
intermitted hematuria completely resolved 3 months after the
deﬁnitive SBRT treatment. Most recent CBC showed Hgb of 10.2,
HCT of 31.1, and MCV of 85.6.Discussion
Renal cell carcinoma was traditionally considered to be rela-
tively radio-resistant to a conventionally fractionated radiation
therapy.2,3 A detailed analysis of radiation survival curves of human
renal tumor cell lines revealed that radiation doses of up to 6 Gy
have relativelymild effects on renal tumor cell viability, while doses
above 6 Gy cause an exponential decrease in cell survival in the
in vitro clonogenic assay.3 Therefore, failure of a conventionalFigure 2. MRI of abdomen with contrast showing an irregular slightly contrast
enhancing lobulated mass projecting off the anterior mid-portion of the right kidney.radiation therapy to show a signiﬁcant beneﬁt for patients with RCC
can perhaps be explained by a relatively low dose per fraction (1.8e
2 Gy) which, according to the above mentioned studies, is not
sufﬁcient to eliminate themajority of renal tumor cells.3 In contrast,
stereotactic body radiation therapy (SBRT) delivers a much higher
dose per fraction (8 Gy or higher), which is expected to kill the
majority of the renal tumor cells based on the in vitro studies.5
Since SBRT is highly effective in destroying tumor vasculature, it
is expected to be beneﬁcial for highly vascularized tumors, espe-
cially in combinationwith anti-angiogenic agents. Therefore, a new
clinical trial is urgently needed to evaluate the effectiveness of SBRT
in combination with anti-VEGF for RCC treatment.5Conclusions
Image-guided high dose SBRT appears to be an effective treat-
ment option for palliative symptomatic management of the inop-
erable RCC. Although our case report does not warrant change in
clinical practice, we hope to highlight this technique for unresect-
able RCC patients. The relatively small number of clinical trials
evaluating SBRT effectiveness in RCC treatment may reﬂect lack of
referral of these patients for RT as RCC was traditionally considered
to be a radio-resistant tumor.Conﬂict of interest
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